Table 1.
General characteristics of studies included in the meta-analysis
| References | Country | Cancer type | Case No. | Male/Female | Age, median | Detect method | Cut-off | Follow-up months (Range) | Survival analysis | HR obtained | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Yao.X.F /201721 |
China | OCC | 120 | 75/45 | 57.6 | IHC | score ≥ 7 |
66 (8–116) |
OS (M) | Curve | 8 |
|
Terashita.K /201622 |
Japan | ICC | 102 | 63/39 | 64 | IHC | score > 40 |
35 (3–170) |
OS (U) | Direct | 8 |
|
Wu.D.W /201610 |
China | CRC | 145 | NR | NR | IHC | score > 150 |
47.7 (3.4–85.7) |
OS (M) | Direct | 7 |
|
Goscinski.M /201519 |
Norway | ESCC | 151 | 92/59 | NR | IHC | staining > 50% | 60 | OS (U) | Curve | 7 |
|
Murai.T /201413 |
Japan | GC | 116 | 83/33 | 64 | qRT-PCR | mRNA ≥0.0217 | 60 | OS (M) | Curve | 7 |
|
Yang.X.Z /201420 |
China | ESCC | 100 | 69/31 | 50 | IHC | score > 4.90 |
32 (3–60) |
OS (U) | Curve | 8 |
|
Bronsert.P /201417 |
Germany | PC | 112 | 55/57 | 67 | IHC | score ≥ 2 | 50 | OS (U) | Direct | 7 |
|
Hashiguchi.M /201315 |
Japan | HCC | 108 | 85/23 | 65.3 | IHC | staining > 1% | 60 |
OS (U) OS (M) |
Direct Direct |
8 |
|
Zhang.G.J /201311 |
China | CRC | 92 | 50/42 | 65 | qRT-PCR | > median value | 60 |
OS (U) OS (M) |
Direct Direct |
8 |
|
Okugawa.Y /201214 |
Japan | GC | 134 | 106/28 | 67 | qRT-PCR | mRNA > 30.15 |
23 (1–79) |
OS (U) OS (M) |
Direct Direct |
8 |
|
Zhou.Y.M /201216 |
China | HCC | 110 | 98/12 | 54 | WB | expression> 30% | 60 | OS (M) | Curve | 7 |
|
Kurahara.H /201218 |
Japan | PC | 76 | 52/24 | 67 | IHC | staining≥10% | 60 | OS (U) | Curve | 7 |
|
Singh.A /201112 |
America | CRC | 250 | 136/114 | 64.6 | gene chip | >median value |
45 (0.4–142) |
OS (U) | Curve | 6 |
Abbreviations: ZEB-1 zinc finger E-box-binding homebox 1, IHC immunohistochemistry, qRT-PCR quantitative real time polymerase chain reaction, WB western blotting, OS overall survival, M multivariate analysis, U univariate analysis, NR not reported, NOS Newcastle-Ottawa scale, OCC oral cavity carcinoma, ICC intrahepatic cholangiocarcinoma, CRC colorectal cancer, ESCC esophageal squamous cell carcinoma, GC gastric cancer, PC pancreatic cancer, HCC hepatocellular carcinoma